Moreover, a longitudinal study of 187 patients with type 2 diabetes reported that a reduced baseline level of CD34+ cells predicted microvascular outcomes after a mean follow‐up of 3.9 years.25 The gene discussed is CD34; the disease is type 2 diabetes mellitus.